MDB Capital President and Chief Market Strategist Lou Basenese talks with Dr. James J. Lalonde, a recognized leader in the field of synthetic biology and Invizyne board member on July 17, 2024.

Invizyne is a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, which recently filed a registration statement for an initial public offering (IPO). MDB Capital is acting as the sole underwriter for the offering.

​

The information contained in this presentation has been prepared to assist interested parties in making their own evaluation of the investment opportunity related to the Company and does not purport to be all-inclusive or to contain all of the information that a prospective investor may desire. In all cases, interested parties should conduct their own investigation and analysis of the data set forth in this presentation and the registration statement for the offering. The Company has not assumed any responsibility for independent verification of any of the forward-looking information contained in this presentation or the related registration statement, including projections and future events and assumptions on which the projections and future events are based. None of the Company or their respective affiliates and representatives makes any representation or warranty (expressed or implied) as to the accuracy or completeness of the forward-looking information contained in this presentation and the related registration statement. Those parties or entities expressly disclaim any and all liability based on or relating to any representations or warranties (expressed or implied) contained in, or errors or omission from, this presentation and the related registration statement or based on or relating to the recipient’s use or the use by any of its affiliates or representatives of this presentation or the related the registration statement or any other written or oral communications transmitted to the recipient or any of its affiliates or representatives in the course of its investment evaluation related to this investment opportunity.

The offering will be made only by means of a prospectus forming a part of the registration statement on Form S-1 relating to these securities that has been filed by the Company with the U.S. Securities and Exchange Commission but has not become effective. The common stock of Invizyne Technologies, Inc. may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. For additional information on Invizyne Technologies, Inc. and the offering, please review the current registration statement on Form S-1 (# 333-276987) that can be found at SEC.gov EDGAR Entity Landing Page: sec.gov/edgar/search/#/ciks=0002010788. A prospectus may also be obtained from MDB Capital by writing to MDB Capital, Prospectus Department, 14135 Midway Road, Suite G-150, Addison, Texas 75001 or emailing community@mdb.com.

Securities offered by the Company are highly speculative. Investing in the shares of common stock of the Company involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment in the Company common stock could be illiquid for an indefinite period of time.

Prior to this offering, there has been no public market for the shares of common stock of the Company. The Company has applied to list its shares of common stock on the Nasdaq Capital Market, sometimes referred to as “Nasdaq.” The listing will not be approved until the time of the offering. No assurance can be given that the application will be approved or that an active trading market for the shares of common stock will develop. The Company will not consummate and close this offering without a listing approval letter from Nasdaq. If the Company does not receive a Nasdaq listing approval, they will terminate the offering.

MDB Capital is required to provide you with certain disclosures and informational resources pertaining to your account and investment activity.

Please follow the link below to review MDB Capital’s Form CRS and additional relevant disclosures:
mdb.com/disclosures.

NOTICE: Securities trading, account management, and investment banking services are offered by MDB Capital, a registered broker-dealer and member of FINRA and SIPC. Unless clearly stated, nothing herein shall be construed to be an offer to sell, nor a solicitation of an offer to buy, any financial product.